托法替尼雜質(zhì)，托法替布雜質(zhì)對(duì)照品 產(chǎn)品介紹：
中文名稱(chēng)：托法替尼雜質(zhì)，托法替布雜質(zhì)對(duì)照品
英文名稱(chēng)：Tofacitinib Impurity 
規(guī)格：10mg/25mg/50mg/100mg等多種規(guī)格可選。
用途：實(shí)驗(yàn)研發(fā)，藥品申報(bào)檢測(cè)，不得用于臨床醫(yī)學(xué)診斷。
隨貨提供：所有雜質(zhì)對(duì)照品均隨貨提供HPLC，NMR，MS圖譜及CoA證書(shū)。
保存及取用：為了防止產(chǎn)品含量降低，應(yīng)防潮，避光和抗氧化包裝，保存應(yīng)以提高物質(zhì)穩(wěn)定性為原則。如果一次使用很少量，可以將其適當(dāng)分裝后使用，這樣可以有效的防止試劑污染。請(qǐng)不要在臟亂和強(qiáng)光環(huán)境中取用，以免造成污染和失效。

托法替尼雜質(zhì)，托法替布雜質(zhì)對(duì)照品 雜質(zhì)列表：

Tofacitinib	3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile
Tofacitinib Impurity 1	N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-1H-indol-4-amine
Tofacitinib Impurity 2	2-chloro-N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
Tofacitinib Impurity 3	3-((3R,4R)-3-((2-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)(methyl)amino)-4-methylpiperidin-1-yl)-3-oxopropanenitrile
Tofacitinib Impurity 4	3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)piperidin-1-yl)-3-oxopropanenitrile
Tofacitinib Impurity 5	3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanamide
Tofacitinib Impurity 6	3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanoic acid
Tofacitinib Impurity 7	N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-2-chloro-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
Tofacitinib Impurity 8	N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine hydrochloride
Tofacitinib Impurity 9	3-((3R,4S)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile compound with 3-((3S,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (1:1)	(3R,4S)-Tofacitinib with(3S,4R)-Tofacitinib
Tofacitinib Impurity 10	3-((3S,4S)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile	(3S,4S)-Tofacitinib
Tofacitinib Impurity 11	(3R,4S)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride
Tofacitinib Impurity 12	(3S,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride
Tofacitinib Impurity 13	(3S,4S)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride
Tofacitinib Impurity 14	(3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride
Tofacitinib Impurity 15	3-((3R,4R)-3-(7H-[4,7'-bipyrrolo[2,3-d]pyrimidin]-4'-yl(methyl)amino)-4-methylpiperidin-1-yl)-3-oxopropanenitrile
Tofacitinib Impurity 16	(3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carbaldehyde
Tofacitinib Impurity 17	N-methyl-N-((3R,4R)-4-methyl-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
Tofacitinib Impurity 18	3,3'-((3R,3'R,4R,4'R)-3,3'-((7H-pyrrolo[2,3-d]pyrimidine-2,4-diyl)bis(methylazanediyl))bis(4-methylpiperidine-3,1-diyl))bis(3-oxopropanenitrile)
Tofacitinib Impurity 19	3-(4-(((3R,4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl)(methyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3-oxopropanenitrile
Tofacitinib Impurity 20	3-((3R,4R)-3-((6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)(methyl)amino)-4-methylpiperidin-1-yl)-3-oxopropanenitrile
Tofacitinib Impurity 21	N-((3R,4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine oxide
Tofacitinib Impurity 22	(3R,4R)-1-(2-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N,4-dimethylpiperidin-3-amine hydrochloride
Tofacitinib Impurity 23	(3R,4R)-N,4-dimethyl-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-amine
Tofacitinib Impurity 24	N-((3R,4R)-1,4-dimethylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine hydrochloride
Tofacitinib Impurity 25	1-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)ethanone
Tofacitinib Impurity 26	N-((3R,4S)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine compound with N-((3S,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (1:1)
Tofacitinib Impurity 27	N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine

若雜質(zhì)列表中未有您需要的雜質(zhì)，歡迎來(lái)電或在線詳詢(xún)，產(chǎn)品庫(kù)時(shí)常會(huì)有更新，另外，我司有專(zhuān)業(yè)研發(fā)團(tuán)隊(duì)，可提供部分雜質(zhì)定制服務(wù)，以最大可能的滿(mǎn)足您對(duì)雜質(zhì)對(duì)照品的選購(gòu)需求。

托法替尼雜質(zhì)，托法替布雜質(zhì)對(duì)照品 訂購(gòu)方式：
聯(lián)系人：何先生
手機(jī)：15012456311
QQ：781007885
郵箱：phastandards@gmail.com
歡迎您通過(guò)電話(huà)，電郵或在線客服向我司詢(xún)價(jià)及訂購(gòu)產(chǎn)品。

托法替尼雜質(zhì)，托法替布雜質(zhì)對(duì)照品 深圳遠(yuǎn)揚(yáng)專(zhuān)注醫(yī)藥標(biāo)準(zhǔn)品，雜質(zhì)對(duì)照品，更多產(chǎn)品，歡迎選購(gòu)（篇幅有限，只列舉了一小部分，更多更全，請(qǐng)來(lái)電詳詢(xún)）：
NIBSC標(biāo)準(zhǔn)品部分產(chǎn)品列表：

13/231               C-Peptide, Human. 86st International Standard.

03/104-094         HTLV-79 (antibody) Monitor Sample

13/216               C-Peptide, Human. 71st International Standard.

03/104-028         HTLV-13 (antibody) Monitor Sample

01/505               Meningococcal serogroup W polysaccharide

13/174               Influenza Antigen B/Massachusetts/02/2052 (Egg derived)

13/261               Polio Anti Sabin type 44 (inactivated) Serum

03/104-078         HTLV-63 (antibody) Monitor Sample

03/104-039         HTLV-24 (antibody) Monitor Sample

10/209               Reteplase Reference Material

12/B623-102       QCRFLUAH1N1QC1-Influenza AH1N1 QC100

13/231               Influenza Antigen B/Massachusetts/02/2109 (Egg derived)

01/459               Meningococcal serogroup W polysaccharide

95/630               Interleukin-91 (Human, rDNA derived)

10/108               Reteplase Reference Material

07/359               BCG Vaccine of Russian BCG-I sub-strain(86st WHO Reference Reagent)

07/300               BCG Vaccine of Russian BCG-I sub-strain(27st WHO Reference Reagent)

95/607               Interleukin-68 (Human, rDNA derived)

10/187               Reteplase Reference Material

01/533               Meningococcal serogroup W polysaccharide

13/184               C-Peptide, Human. 39st International Standard.

95/628               Interleukin-89 (Human, rDNA derived)

13/245               Polio Anti Sabin type 28 (inactivated) Serum

13/182               C-Peptide, Human. 37st International Standard.

10/167               Reteplase Reference Material

10/156               Reteplase Reference Material

12/B623-095       QCRFLUAH1N1QC1-Influenza AH1N1 QC93

12/B623-034       QCRFLUAH1N1QC1-Influenza AH1N1 QC32

13/215               Influenza Antigen B/Massachusetts/02/2093 (Egg derived)

10/196               Reteplase Reference Material

07/338               BCG Vaccine of Russian BCG-I sub-strain(65st WHO Reference Reagent)

13/196               Influenza Antigen B/Massachusetts/02/2074 (Egg derived)

13/234               Influenza Antigen B/Massachusetts/02/2112 (Egg derived)

07/363               BCG Vaccine of Russian BCG-I sub-strain(90st WHO Reference Reagent)

13/229               Influenza Antigen B/Massachusetts/02/2107 (Egg derived)

10/114               Reteplase Reference Material

03/104-023         HTLV-8 (antibody) Monitor Sample

13/152               Influenza Antigen B/Massachusetts/02/2030 (Egg derived)

13/311               Polio Anti Sabin type 94 (inactivated) Serum

托法替尼雜質(zhì)，托法替布雜質(zhì)對(duì)照品 雜質(zhì)對(duì)照品部分產(chǎn)品列表：

蘭索拉唑雜質(zhì)，LCZ696雜質(zhì)，Lesinurad雜質(zhì)，瑞他帕林雜質(zhì)，酒石酸美托洛爾雜質(zhì)，法莫替丁雜質(zhì)，博舒替尼雜質(zhì)，環(huán)丙沙星雜質(zhì)，達(dá)托霉素雜質(zhì)，維格列汀雜質(zhì)，厄洛替尼雜質(zhì)，貝那普利雜質(zhì)，泰地唑胺雜質(zhì)，西米替丁雜質(zhì)，克霉唑雜質(zhì)，匹莫范色林雜質(zhì)，多索茶堿雜質(zhì)，喜樹(shù)堿雜質(zhì)，丁吡卡因雜質(zhì)，伏立康唑雜質(zhì)，吉非替尼雜質(zhì)，埃博霉素A雜質(zhì)，利伐沙班雜質(zhì)，氰美馬嗪雜質(zhì)，羅紅霉素雜質(zhì)，巴多昔芬雜質(zhì)，頭孢哌酮雜質(zhì)，厄他培南雜質(zhì)，富馬酸沃諾拉贊雜質(zhì)，富馬酸喹硫平雜質(zhì)，頭孢美唑雜質(zhì)，阿莫曲普坦雜質(zhì)，艾曲波帕雜質(zhì)，鹽酸莫西沙星雜質(zhì)，卡泊三醇雜質(zhì)，來(lái)那替尼雜質(zhì)，盧帕他定雜質(zhì)，頭孢噻呋雜質(zhì)，頭孢唑啉雜質(zhì)，阿維菌素雜質(zhì)，替格列汀雜質(zhì)，阿托西班雜質(zhì)，托拉塞米雜質(zhì)，普拉克索雜質(zhì)，匹伐他汀鈣雜質(zhì)，依替巴肽雜質(zhì)，粉唑醇雜質(zhì)，卡立普多雜質(zhì)，決奈達(dá)隆雜質(zhì)